Search results
Showing 1411 to 1425 of 1505 results for patients and public
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113
In development Reference number: GID-TA11025 Expected publication date: TBC
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Discontinued Reference number: GID-TAG387
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.
Discontinued Reference number: GID-TAG402
Biographies and registered interests for members of the Technology Appraisal Committee C
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Biographies and registered interests for members of the Technology Appraisal Committee A
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Same time decisions on licensing and value - what pharmaceutical companies need to know
Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.
Day-to-day decision making is the responsibility of NICE's executive team.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.